Bayer (BAYN) Receives €116.95 Average PT from Brokerages

Shares of Bayer (FRA:BAYN) have been given an average rating of “Buy” by the twenty-three analysts that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, seven have given a hold rating and fifteen have given a buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is €116.95 ($139.23).

A number of research analysts have recently commented on the company. Deutsche Bank reaffirmed a “buy” rating on shares of Bayer in a research report on Friday, May 4th. Nord/LB set a €94.00 ($111.90) price target on Bayer and gave the company a “neutral” rating in a research report on Thursday, May 3rd. Goldman Sachs set a €125.00 ($148.81) price target on Bayer and gave the company a “buy” rating in a research report on Thursday, May 3rd. UBS set a €120.00 ($142.86) price target on Bayer and gave the company a “buy” rating in a research report on Thursday, May 3rd. Finally, equinet set a €118.00 ($140.48) price target on Bayer and gave the company a “buy” rating in a research report on Thursday, May 3rd.

Bayer traded down €0.14 ($0.17), hitting €104.36 ($124.24), during midday trading on Monday, MarketBeat reports. The company’s stock had a trading volume of 3,562,919 shares. Bayer has a 1 year low of €91.58 ($109.02) and a 1 year high of €123.82 ($147.40).

Bayer Company Profile

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply